Does mefenamic acid (Nonsteroidal Anti-Inflammatory Drug (NSAID)) slow down menstruation in females of reproductive age, particularly those with heavy menstrual bleeding or dysmenorrhea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Mefenamic Acid Slow Down Menstruation?

Yes, mefenamic acid reduces menstrual blood loss by approximately 20-50% and shortens the duration of menstruation in women with heavy menstrual bleeding. 1, 2

Mechanism and Efficacy

Mefenamic acid works by reducing prostaglandin synthesis, which directly decreases menstrual blood flow and endometrial inflammation. 3, 4 The evidence demonstrates:

  • Menstrual blood loss reduction: Mefenamic acid reduces median menstrual blood loss from 123 mL to 81 mL per cycle (a 34% reduction) in women with objectively measured menorrhagia. 2

  • Duration of bleeding: Treatment decreases the median number of bleeding days from 7 days to 5 days. 2

  • Pad count reduction: Women using mefenamic acid experience a decrease in pad usage from 23.20 to 14.33 pads per cycle. 5

Clinical Application and Dosing

Standard treatment protocol: Administer 500 mg three times daily during menstruation for 5-7 days. 1, 3, 2 This short-term regimen is recommended by the CDC as first-line therapy for:

  • Heavy menstrual bleeding in women using copper IUDs 1, 6
  • Breakthrough bleeding with DMPA (depot medroxyprogesterone acetate) 1
  • Primary dysmenorrhea with heavy bleeding 3, 7

Comparative Effectiveness

When compared to other treatments:

  • Versus placebo: Mefenamic acid produces complete symptom relief in 88.6% of patients versus 13% with placebo. 7, 8

  • Versus other NSAIDs: No significant difference in efficacy between mefenamic acid and other NSAIDs (naproxen, indomethacin, flufenamic acid). 1, 9, 8

  • Versus tranexamic acid or danazol: Less effective than these agents but with fewer adverse effects. 8

  • Versus norethisterone: Similar efficacy in reducing menstrual blood loss (both reduced bleeding by approximately 30-40%). 2

Important Clinical Caveats

Before prescribing mefenamic acid, rule out:

  • Pregnancy 4, 6
  • Sexually transmitted infections 1, 6
  • Structural pathology (fibroids, polyps) 1, 6
  • IUD displacement (if applicable) 6

Contraindications and warnings:

  • Avoid in cardiovascular disease: NSAIDs increase risk of myocardial infarction and thrombosis. 3, 4, 6
  • Avoid aspirin: May paradoxically increase bleeding in women with lower baseline menstrual blood loss. 1, 6
  • Use with caution: In patients with peptic ulcer disease, advanced age (>60 years), or concurrent corticosteroid therapy. 3

Treatment Limitations

Despite effectiveness, approximately 52% of women remain menorrhagic after 2 months of mefenamic acid treatment. 2 If bleeding persists and is unacceptable to the patient:

  • Consider second-line hormonal therapy: Combined oral contraceptives or estrogen for 10-20 days (if medically eligible). 1, 6
  • Consider alternative contraceptive methods or the levonorgestrel-releasing IUS, which reduces menstrual blood loss by 71-95%. 6
  • Counsel on method switching if patient finds bleeding unacceptable. 1, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

NSAIDs as First-Line Treatment for Dysmenorrhea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Breakthrough Bleeding on Oral Contraceptives

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Breakthrough Menstrual Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of primary dysmenorrhea with mefenamic acid.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1980

Research

Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.

The Cochrane database of systematic reviews, 2000

Research

Oral contraceptive pills for heavy menstrual bleeding.

The Cochrane database of systematic reviews, 2000

Related Questions

What is more effective for managing heavy menstrual bleeding and dysmenorrhea, Naprogesic (naproxen) or Ponstan (mefenamic acid)?
What is the recommended dosage of Mefenamic acid (nonsteroidal anti-inflammatory drug) for a female patient of reproductive age with dysmenorrhea and no significant medical history?
What's the next step for a 48-year-old woman with heavy menstrual bleeding, uterine polyp, ovarian cyst, dehydration, muscle cramps, and risk of iron deficiency anemia, currently taking naproxen (nonsteroidal anti-inflammatory drug) and iron supplements?
What is the success rate of mefenamic acid in controlling intermenstrual bleeding related to the copper IUD?
How many times can mefenamic acid be used for intermenstrual bleeding caused by a copper IUD?
Is it effective to take buprenorphine (BUP) - naloxone and oxycodone (OXYCODONE) together for a patient with opioid use disorder and chronic pain?
What is the appropriate management for a patient with polyarthritis and sore feet, potentially indicating inflammatory arthritis?
What is the next best step for a patient with pneumonia that has not improved with Augmentin (amoxicillin/clavulanate) and Azithromycin, considering possible resistant bacterial infection or other causes?
What are the diagnostic criteria and treatment options for a patient with suspected Type 2 Diabetes Mellitus (DM)?
What is the condition characterized by redness and chronic discoloration of the lower legs in a patient with chronic venous insufficiency (CVI) and longstanding edema?
What does an elevated Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP) indicate in a patient presenting with diarrhea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.